TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive In Brief: San Antonia Cancer Institute Designated Comprehensive; Yeast DNA Described May 3, 1996
TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012